Tested Applications
| Positive WB detected in | HL-60 cells, PC-3 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:200-1:1000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
15497-1-AP targets DR5-Specific in WB, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | tumor necrosis factor receptor superfamily, member 10b |
| Calculated Molecular Weight | 48 kDa |
| Observed Molecular Weight | 58-60 kDa, 45-50 kDa, 32 kDa |
| GenBank Accession Number | NM_003842 |
| Gene Symbol | DR5 |
| Gene ID (NCBI) | 8795 |
| RRID | AB_2240702 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O14763 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
TNFRSF10B, also known as CD262, DR5, TRAILR2, TRICK2 and KILLER, is a widely expressed single-pass type I membrane protein belonging to the tumour necrosis factor receptor superfamily (TNFRSF). It is a receptor for TNF-related apoptosis-inducing ligand (TRAIL), which is a member of the tumor necrosis factor (TNF) family of cytokines and induces apoptosis in a wide variety of cells (PMID: 9311998). TNFRSF10B contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain (DD), through which TNFRSF10B is capable to transmit the apoptotic signal (PMID: 9311998; 20531300). In PDAC cells, especially Panc89 cells, it expresses additionally to the approximately 48 and 40 kDa forms of DR5, a faster migrating variant of DR5 of about 32 kDa(PMID:20354842). The TRAIL receptor 2 (death receptor 5, or DR5) forms receptor dimers in a ligand-dependent manner, and these receptor dimers exist within high molecular weight networks(Dr. Jonathan N. Sachs,2012).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for DR5-Specific antibody 15497-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
15497-1-AP is an anti-DR5 antibody with 18 total citations. Citations appear in journals including Nature Communications, Acta Pharmaceutica Sinica B, International Journal of Biological Sciences, Molecular Pharmaceutics, iScience, Journal of Natural Products, and others. Research fields span apoptosis, TRAIL/DR5 signaling, endoplasmic reticulum stress, mitochondrial fission, and anticancer therapy across multiple tumor types including breast, lung, ovarian, gastric, colorectal, and hepatocellular cancers.
| Species | Application | Title |
|---|---|---|
Nat Commun A non-canonical pathway regulates ER stress signaling and blocks ER stress-induced apoptosis and heart failure. | ||
Acta Pharm Sin B Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis | ||
Int J Biol Sci ESRG is critical to maintain the cell survival and self-renewal/pluripotency of hPSCs by collaborating with MCM2 to suppress p53 pathway | ||
Mar Drugs Targeting YY1-DR5 Axis by Pyripyropene O as a Novel Therapeutic Strategy Against Prostate Cancer: Molecular Mechanisms and In Vivo Zebrafish Validation | ||
Biochim Biophys Acta Mol Basis Dis Synergistic apoptosis-sensitizing effect of PD-L1 inhibitor ARB-272572 encapsulated in TRAIL-expressing extracellular vesicles for renal cell carcinoma therapy. | ||
Mol Pharm Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody |
